James Willhite was an editor with The Wall Street Journal's money & investing team based in London.

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in ...

Novavax is working closely with federal drug regulators to get full approval for its COVID shot. The vaccine is the only ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA ...

Measles is caused by a highly contagious virus that’s airborne and spreads easily when an infected person breathes, sneezes ...

Researchers have uncovered a critical, previously underappreciated role for B cells in vaccine protection. Best known for producing antibodies, B cells also guide other immune cells, specifically CD8 ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

The US Centers for Disease Control and Prevention's outside panel of vaccine experts this week discussed narrowing ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...